KDM6A and neoplasm: Yuichiro et al. (Itoh et al., 2019) found that a KDM6A deletion mutation resulted in the activation of Th1 and Th2 cell pathways and the down regulation of an inflammatory response in CD4+ T cells, which is likely to contribute to a pro-tumor microenvironment.